AI illustration · not actual product photoDetails from the source.
Source-listed TB10mg+BPC-157 10mg+GHK50 (SKU BBG70): 70mg*10Vials. PriceList(1).pdf lists 165 per 10 vials but does not specify currency; the website displays $165 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- BBG70
- Source specification
- 70mg*10Vials
- Source document
- PriceList(1).pdf, page 4
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Multi-ingredient peptide/copper-peptide blend listing, not a single peptide. The label identifies BPC-157 and “GHK50,” but does not verify the chemical form behind GHK50. “TB10mg” is chemically ambiguous and cannot be equated to TB-500, thymosin beta-4, or a specific fragment or salt without owner documentation. Source listing: SKU BBG70; *10Vials; price 165 per 10 vials, currency unstated. No supplier-specific vial identity is inferred.
Biological mechanism
BPC-157 is described in literature as a synthetic 15-amino-acid peptide. Proposed signaling effects include vascular/repair pathways involving VEGFR2 and nitric oxide, cell migration and inflammatory signaling; these claims are mainly preclinical and are not an established human mechanism. GHK is a tripeptide that binds copper; GHK-Cu research proposes effects on gene expression, fibroblast activity and extracellular-matrix/collagen processes. The catalogue label says GHK50, not GHK-Cu, and does not document the chemical form. The mechanism of “TB10mg” cannot be described without identifying it. No mechanism has been established for this combination. [1] [2] [3] [4]
Research focus
BPC-157 is studied mainly in laboratory and animal models of tissue repair, musculoskeletal injury and gastrointestinal protection, with very limited exploratory human research. GHK/GHK-Cu has laboratory and animal research on skin and tissue biology, plus small human studies of topical cosmetic formulations. Thymosin beta-4 and a distinct TB-500 fragment have been investigated in separate research contexts, but the catalogue label does not resolve which is present. No direct clinical evidence for the three-component blend was identified.
Potential applications in the evidence
Only as research topics, not established uses: BPC-157 has been investigated in preclinical tissue-repair and gastrointestinal models and in small exploratory human reports involving knee pain and interstitial cystitis. GHK-Cu research includes skin repair and cosmetic skin appearance, with human studies largely involving topical products. Wound-healing work on a specifically identified TB-500 fragment or full-length thymosin beta-4 cannot be transferred to this unidentified “TB” ingredient. There is no evidence that standalone research establishes an application for this blend.
Human evidence
Human evidence does not establish effectiveness or safety for this blend. A 2024 uncontrolled pilot report described 12 people with interstitial cystitis and reported symptom improvement after BPC-157, but its small sample, absence of a control group and limited design do not establish efficacy or safety. Reviews describe only a few BPC-157 human studies overall. Human GHK-Cu reports largely concern topical cosmetic formulations and do not establish effects of this vial or systemic use. No human study of this exact combination was identified. [3] [4] [5]
Known and potential effects
No clinically established effects are known for this exact blend. Small exploratory reports describe outcomes for standalone BPC-157; review literature describes changes in skin appearance with topical GHK-Cu formulations. Those findings are preliminary, formulation- and context-specific, and do not establish effects of BBG70. The blend has no characterized adverse-effect profile. A small BPC-157 pilot reporting no adverse events cannot rule out uncommon, delayed or product-quality-related harms. [3] [4] [5]
Safety and contraindications
FDA materials raise concerns relevant to peptide bulk substances, including uncertainty in chemical identity, potential peptide impurities and possible immunogenicity for some routes. The catalogue provides no route, manufacturer, lot, CoA, sterility/endotoxin/particulate documentation, purity, stability, or allergy information. Product-specific contraindications cannot be verified; no reliable safety profile for this combination or defined safe population is established. Do not treat missing adverse-event reports or standalone ingredient data as evidence that the blend is safe. [1] [2]
U.S. FDA / regulatory status
U.S. FDA status as of 2026-10-30: FDA briefing materials state the BPC-157-related and TB-500-related substances evaluated were not components of FDA-approved drugs; those materials concern evaluation for the 503A compounding bulks list, not approval of a drug. FDA's May 2026 list places GHK-Cu except for injectable routes in Category 1 (under evaluation), not as an FDA-approved product, and states a committee consultation was planned before February 2027. Ingredient-level status does not determine the status of this supplier-specific blend. The catalogue does not identify a manufacturer, lot, exact formulation/source, jurisdiction, regulatory pathway, or approval number. FDA approval of this exact vial cannot be verified; no approval transfers from any standalone ingredient or other branded formulation. [1] [2] [6]
Evidence limitations
The source label and family ID do not establish the exact identity, salt, sequence or source of “TB10mg,” nor do they verify whether GHK50 is GHK-Cu. The quantity convention, route, product formulation, manufacturer and quality attributes are undocumented. Evidence is dominated by preclinical studies or small/exploratory human studies and is not evidence for the blend. No direct clinical study of the combination was found. Regulatory materials reviewed address specific ingredients/routes and compounding-list evaluation; they do not resolve the approval or quality status of this vial.
Supporting sources
- FDA Evaluation of TB-500-Related Bulk Drug Substances (TB-500 (Free Base) and TB-500 Acetate) U.S. Food and Drug Administration · Regulatory briefing document. Supports: Explains that TB-500 is a common, ambiguous name; describes a specific seven-amino-acid fragment; notes identity/characterization concerns and that the evaluated substances were not components of FDA-approved drugs.
- FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (Free Base) and BPC-157 Acetate) U.S. Food and Drug Administration · Regulatory briefing document. Supports: Supports BPC-157 peptide identity, salt and naming ambiguity, limited evidence and safety concerns, and distinction between compounding-list review and FDA approval.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A U.S. Food and Drug Administration · Regulatory database/list. Supports: Supports the May 2026 GHK-Cu Category 1 status except injectable routes, clarifying that Category 1 is under evaluation and not product approval.
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine / PubMed Central · Peer-reviewed review. Supports: Supports proposed BPC-157 mechanisms, extensive animal/preclinical research, the very limited human evidence base and research limitations.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data International Journal of Molecular Sciences / PubMed Central · Peer-reviewed review. Supports: Supports GHK/GHK-Cu identity and proposed biological mechanisms; summarizes preclinical work and small human topical cosmetic studies, which are not evidence for this vial.
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Alternative Therapies in Health and Medicine / PubMed · Human pilot study record. Supports: Supports the description and limitations of a small uncontrolled human pilot report in interstitial cystitis, including its reported outcomes and lack of reported adverse events.